XML 53 R41.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Certain Transactions - Business Acquisitions - Additional Information (Detail) shares in Millions, $ in Millions |  |  |  |  |  |  | 1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Jan. 31, 2018 USD ($) | Jan. 08, 2018 USD ($) | May 12, 2017 USD ($) | Oct. 03, 2016 USD ($) | Aug. 02, 2016 USD ($) shares | Mar. 03, 2016 USD ($) | Dec. 31, 2016 USD ($) | Nov. 30, 2016 USD ($) | Sep. 30, 2016 USD ($) Lawsuit | Sep. 30, 2018 USD ($) | Mar. 31, 2018 USD ($) | Sep. 30, 2017 USD ($) | Jun. 30, 2017 USD ($) | Sep. 30, 2018 USD ($) | Sep. 30, 2017 USD ($) | Dec. 31, 2017 USD ($) | Sep. 17, 2017 USD ($) | Oct. 31, 2016 USD ($)
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net gain on sale |  |  |  |  |  |  |  |  |  | $ 31 |  |  |  | $ 114 |  |  |  |
Impairment of equity investment |  |  |  |  |  |  |  |  |  |  |  |  |  | 103 |  |  |  |
Other Income |  |  |  |  |  |  |  |  |  | 35 |  | $ 4 |  | 334 | $ 100 |  |  |
Allergan plc [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Allergan one time payment to Teva | $ 703 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
P&G [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Other Income |  |  |  |  |  |  |  |  |  |  |  |  |  | 50 |  |  |  |
Women Health [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Goodwill |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 329 |  |
Net gain on sale | 93 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cost of sale of business | $ 2 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Women Health [Member] | CVC Capital Partners Fund VI [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Sale agreement with CVC capital partners fund VI |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 703 |
Actavis [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cash consideration |  |  |  |  | $ 33,400 |  |  |  |  |  |  |  |  |  |  |  |  |
Shares issued as consideration for the acquisition | shares |  |  |  |  | 100.3 |  |  |  |  |  |  |  |  |  |  |  |  |
Cash consideration working capital true up |  |  |  |  |  |  |  |  |  | 1,400 |  |  |  | 1,400 |  |  |  |
Anda [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cash consideration |  |  |  | $ 500 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Rimsa [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cash consideration |  |  |  |  |  | $ 2,300 |  |  |  |  |  |  |  |  |  |  |  |
Number of lawsuits filed | Lawsuit |  |  |  |  |  |  |  |  | 2 |  |  |  |  |  |  |  |  |
Alder [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment |  | $ 25 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative agreement milestone payments |  | $ 175 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Otsuka [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment |  |  | $ 50 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Attenukine [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment |  |  |  |  |  |  | $ 30 |  |  |  |  |  |  |  |  |  |  |
Additional considerations |  |  |  |  |  |  | $ 280 |  |  |  |  |  |  |  |  |  |  |
Ninlaro [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment |  |  |  |  |  |  |  | $ 150 |  |  |  |  |  |  |  |  |  |
Payment |  |  |  |  |  |  |  | $ 150 |  |  |  |  |  |  |  |  |  |
Celltrion [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Refundable payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 60
Total associated cost |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 160
Regeneron [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment |  |  |  |  |  |  |  |  | $ 250 |  |  |  |  |  |  |  |  |
Collaborative agreement milestone payments |  |  |  |  |  |  |  |  |  |  | $ 35 |  | $ 25 |  |  |  |  |
Research and development costs |  |  |  |  |  |  |  |  | $ 1,000 |  |  |  |  |  |  |  |  |
Collaborative agreement, provision for milestone payments |  |  |  |  |  |  |  |  |  | $ 60 |  |  |  | $ 60 |  |  |  |
New Chapter Inc [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Impairment of equity investment |  |  |  |  |  |  |  |  |  |  | 94 |  |  |  |  |  |  |
India [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Impairment |  |  |  |  |  |  |  |  |  |  | $ 64 |  |  |  |  |  |  |

X
- Definition Additional Considerations + References No definition available. + Details
Name: | teva_AdditionalConsiderations
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Cash Consideration Working Capital True Up + References No definition available. + Details
Name: | teva_CashConsiderationWorkingCapitalTrueUp
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Collaborative Agreement Milestone Payments + References No definition available. + Details
Name: | teva_CollaborativeAgreementMilestonePayments
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaborative Agreement Provision For Milestone Payments + References No definition available. + Details
Name: | teva_CollaborativeAgreementProvisionForMilestonePayments
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Cost Of Sale Of Business + References No definition available. + Details
Name: | teva_CostOfSaleOfBusiness
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number Of Lawsuits Filed + References No definition available. + Details
Name: | teva_NumberOfLawsuitsFiled
Namespace Prefix: | teva_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition One time payment receivable. + References No definition available. + Details
Name: | teva_OneTimePaymentReceivable
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Payment + References No definition available. + Details
Name: | teva_Payment
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Refundable Payment + References No definition available. + Details
Name: | teva_RefundablePayment
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Research And Development Costs + References No definition available. + Details
Name: | teva_ResearchAndDevelopmentCosts
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Sale agreement price. + References No definition available. + Details
Name: | teva_SaleAgreementPrice
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Total Associated Cost + References No definition available. + Details
Name: | teva_TotalAssociatedCost
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Upfront payments + References No definition available. + Details
Name: | teva_UpfrontPayments
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number of shares of equity interests issued or issuable to acquire entity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (b)(4) -URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479 + Details
Name: | us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_BusinessAcquisitionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1B -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684 + Details
Name: | us-gaap_GainLossOnSaleOfBusiness
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of divestiture of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267 + Details
Name: | us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount by which the fair value of an investment is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 45 -Paragraph 8A -URI http://asc.fasb.org/extlink&oid=109979856&loc=SL6284422-111562 + Details
Name: | us-gaap_ImpairmentOfInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 15 -URI http://asc.fasb.org/extlink&oid=109226348&loc=d3e2611-110228 + Details
Name: | us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of revenue and income classified as other. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.4) -URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263 + Details
Name: | us-gaap_OtherIncome
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (b)(1) -URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585 + Details
Name: | us-gaap_PaymentsToAcquireBusinessesGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=teva_AllerganPlcMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=teva_ProcterAndGambleCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=teva_WomenHealthMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=teva_CvcCapitalPartnersFundViMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=teva_ActavisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=teva_AndaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=teva_RimsaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=teva_AlderMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=teva_OtsukaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=teva_AttenukineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=teva_NinlaroMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=teva_CelltrionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=teva_RegeneronMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=teva_NewChapterIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_IN
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |